Eledon Pharmaceuticals, Inc. Common Stock
Symbol: ELDN (NASDAQ)
2.62
▲ (1.16%) 0.030
Company Description:
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Key Stats
- Today's Open: $2.57
- Today's High: $2.735
- Today's Low: $2.575
- Today's Volume: 1.07M
- Yesterday Close: $2.59
- Yesterday High: $2.635
- Yesterday Low: $2.48
- Yesterday Volume: 762.98K
- Last Min Volume: 10
- Last Min High: $2.62
- Last Min Low: $2.62
- Last Min VWAP: $2.62
Company Profile
- Name: Eledon Pharmaceuticals, Inc. Common Stock
- Website: https://www.eledon.com
- Listed Date: 2014-09-17
- Location: IRVINE, CA
- Market Status: Active
- CIK Number: 0001404281
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $155.09M
- Round Lot: 100
- Outstanding Shares: 59.88M
- Asset Type: CS
RECENT FILINGS FOR ELDN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 10-Q/A | View |
| 2025-08-14 | 10-K/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-06 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-06-12 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-04-29 | ARS | View |
| 2025-04-29 | DEFA14A | View |
| 2025-04-29 | DEF 14A | View |
| 2025-04-14 | PRE 14A | View |
| 2025-04-14 | 8-K/A | View |
| 2025-04-07 | 8-K | View |
| 2025-03-20 | 10-K | View |
| 2025-03-20 | 8-K | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
Latest News on ELDN